How close is DEA to making decision on rescheduling marijuana?
Those keen to know exactly when the U.S. Drug Enforcement Administration will issue its decision on marijuana rescheduling remain frustrated.
Those keen to know exactly when the U.S. Drug Enforcement Administration will issue its decision on marijuana rescheduling remain frustrated.
Marijuana reform garnered only a brief mention during President Joe Biden’s annual State of the Union address on Thursday night.
Major marijuana multistate operator Curaleaf Holdings posted $345.3 million in net revenue for the fourth quarter of 2023, an increase of 1.5% over the same quarter the year before and 3.6% over the third quarter.
The $143 million question on every marijuana executive’s mind these days is: Should my MJ company consider filing a tax refund claim? The best answer is: Some should.
Green Thumb Industries’ plans to be the first multistate operator to sell marijuana at convenience stores is still in the works, company officials said while reporting annual revenue of $1.05 billion.
American commitments in international treaties do not forbid the U.S. Drug Enforcement Administration from rescheduling marijuana as recommended, a California congresswoman told the agency.
A group of reform-minded police chiefs and prosecutors urged the Biden administration in a letter sent Thursday to reclassify marijuana as a less harmful drug under federal law.
Canadian cannabis producer Canopy Growth on Friday reported a shake-up to its board of directors, a lower third-quarter loss and a “singular focus” on marijuana.
Trulieve Cannabis Corp.’s highly publicized $143 million federal income tax refund claims created a frenzy of hope that seems to offer the marijuana industry a way out. But does it?
A federal judge has rejected the latest effort by out-of-state applicants to stop New York state from licensing adult-use marijuana stores, ruling in part that constitutional free-trade protections don’t apply to federally illegal marijuana.
The Drug Enforcement Administration should go beyond health regulators’ marijuana rescheduling recommendation and deschedule the drug entirely, top Democratic U.S. senators wrote in a letter.